Tarsus Pharmaceuticals, Inc. TARS Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value?
- Tarsus Pharmaceuticals, Inc. (TARS) reported share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value of $248.05M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value increased by 88.8% year-over-year, from $131.36M to $248.05M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, aggregate intrinsic value has grown at a 71.0% compound annual growth rate (CAGR), from $16.99M to $248.05M.